ArticlemedRxiv : the preprint server for health sciences2025
A Wearable Infrared Sensor for Detecting Non-ST Segment Elevation Acute Coronary Syndromes.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is conventionally diagnosed using electrocardiography and serial blood biomarker measurements. We investigated a non-invasive, bloodless, and electrode-free diagnostic strategy using a wrist-worn infrared spectrophotometric biosensor (Infrasensor). In a prospective, multicenter study of 595 patients with suspected NSTE-ACS enrolled across 13 sites in two countries, participants were stratified into five analytical cohorts. With 200 multi-ethnic controls and a leave-one-cohort-out external validation, a machine learning model detected high-grade coronary obstruction with an area under the receiver operating characteristic curve (AUC) of 0.87 (95% CI: 0.84-0.90), 90% specificity, and 84% positive predictive value-surpassing standard risk scores. A secondary model predicted freedom from NSTE-ACS and adverse outcomes over 30 days with an AUC of 0.89 (95% CI: 0.87-0.92), 99% sensitivity, and 96% negative predictive value. These findings demonstrate the potential of the Infrasensor as a rapid, scalable point-of-care tool for early risk stratification in NSTE-ACS.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.